Oncolytics Biotech (TSE:ONC) Stock Price Passes Above 200-Day Moving Average of $1.68

Shares of Oncolytics Biotech Inc. (TSE:ONC) crossed above its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of C$1.68 and traded as high as C$1.74. Oncolytics Biotech shares last traded at C$1.69, with a volume of 142,533 shares changing hands.

Wall Street Analyst Weigh In

ONC has been the topic of a number of recent analyst reports. Cantor Fitzgerald reiterated an “overweight” rating on shares of Oncolytics Biotech in a report on Friday, January 12th. Raymond James set a C$3.00 price target on Oncolytics Biotech and gave the company an “outperform” rating in a research note on Thursday, April 4th.

Oncolytics Biotech Trading Up 4.3 %

The business’s 50-day simple moving average is C$1.47 and its two-hundred day simple moving average is C$1.68. The firm has a market capitalization of C$127.46 million, a price-to-earnings ratio of -4.12 and a beta of 1.49. The company has a quick ratio of 8.86, a current ratio of 9.01 and a debt-to-equity ratio of 1.54.

Oncolytics Biotech (TSE:ONC) last posted its quarterly earnings data on Thursday, March 7th. The company reported C($0.05) earnings per share for the quarter, topping analysts’ consensus estimates of C($0.15) by C$0.10. Equities analysts forecast that Oncolytics Biotech Inc. will post -0.41 earnings per share for the current year.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.